LeMaitre Vascular (NASDAQ:LMAT) Issues FY 2024 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its FY 2024 earnings guidance on Thursday. The company provided EPS guidance of 1.820-1.910 for the period, compared to the consensus EPS estimate of 1.770. The company issued revenue guidance of $216.8 million-$220.8 million, compared to the consensus revenue estimate of $215.1 million. LeMaitre Vascular also updated its Q3 guidance to $0.42 to $0.46 EPS.

Analysts Set New Price Targets

A number of research firms have commented on LMAT. Roth Mkm reaffirmed a buy rating and issued a $100.00 target price on shares of LeMaitre Vascular in a research report on Friday, May 31st. StockNews.com cut shares of LeMaitre Vascular from a buy rating to a hold rating in a research note on Friday. Barrington Research upped their price target on LeMaitre Vascular from $79.00 to $92.00 and gave the stock an outperform rating in a research note on Friday. Stifel Nicolaus upgraded LeMaitre Vascular from a hold rating to a buy rating and raised their price objective for the company from $59.00 to $75.00 in a research report on Friday, April 26th. Finally, Roth Capital raised shares of LeMaitre Vascular to a strong-buy rating in a research note on Friday, May 31st. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of Moderate Buy and an average price target of $83.71.

LeMaitre Vascular Stock Down 1.4 %

Shares of LMAT traded down $1.24 during trading on Friday, reaching $85.01. 348,354 shares of the company traded hands, compared to its average volume of 157,693. The stock has a market cap of $1.91 billion, a PE ratio of 56.30, a price-to-earnings-growth ratio of 2.63 and a beta of 0.89. The stock has a 50-day simple moving average of $82.69 and a 200-day simple moving average of $71.68. LeMaitre Vascular has a twelve month low of $44.27 and a twelve month high of $91.76.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.63%. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.37 earnings per share. On average, equities research analysts predict that LeMaitre Vascular will post 1.77 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.75%. The ex-dividend date of this dividend is Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Insider Activity at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 68,906 shares of the business’s stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the completion of the sale, the chief executive officer now owns 2,133,428 shares in the company, valued at approximately $161,500,499.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other LeMaitre Vascular news, CEO George W. Lemaitre sold 68,906 shares of LeMaitre Vascular stock in a transaction on Monday, May 6th. The shares were sold at an average price of $75.70, for a total value of $5,216,184.20. Following the transaction, the chief executive officer now directly owns 2,133,428 shares in the company, valued at $161,500,499.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The disclosure for this sale can be found here. Insiders sold 127,437 shares of company stock valued at $10,076,242 over the last three months. 10.79% of the stock is owned by corporate insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.